Sanofi discusses $275 per Actelion share for potential deal - Bloomberg
Dec 15 (Reuters) - French drugmaker Sanofi is in advanced talks to buy Actelion Ltd and is discussing a price of about $275 per share for the Swiss drugmaker, Bloomberg reported on Thursday.
The potential deal, which could come as soon as next week, would value Actelion at about $29.6 billion, Bloomberg reported, citing people with knowledge of the matter. http://bloom.bg/2hCMRLu
Actelion is in talks with Sanofi about a deal, Reuters reported on Wednesday, after U.S. healthcare group Johnson & Johnson abandoned efforts to buy the company.
Sanofi and Actelion could not immediately be reached for comment.
(Reporting by Ismail Shakil in Bengaluru; Editing by Gopakumar Warrier)
Terms and Privacy Policy